BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

    Not Recruiting
  • participants needed
  • sponsor
    Boehringer Ingelheim
Updated on 21 June 2021
cognitive impairment
acetylcholinesterase inhibitor


The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.

Condition Alzheimer's Disease
Treatment Placebo, BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4
Clinical Study IdentifierNCT02788513
SponsorBoehringer Ingelheim
Last Modified on21 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note